Open AccessAntimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe
Author(s) -
Hélio S. Sader,
Cecília G Carvalhaes,
Leonard R Duncan,
Dee Shortridge
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00211-20
Subject(s) - broth microdilution , haemophilus influenzae , microbiology and biotechnology , antimicrobial , haemophilus , liter , tazobactam , medicine , minimum inhibitory concentration , biology , antibiotics , bacteria , antibiotic resistance , imipenem , genetics
Nine hundred Haemophilus influenzae clinical isolates from 83 U.S. and European medical centers were tested for susceptibility by reference broth microdilution methods against ceftolozane-tazobactam and comparators. Results were stratified by β-lactamase production and infection type. Overall, ceftolozane-tazobactam MIC 50/90 values were 0.12/0.25 mg/liter, and 99.0% of isolates were inhibited at the susceptible breakpoint of ≤0.5 mg/liter; the highest MIC value was only 2 mg/liter. Our results support using ceftolozane-tazobactam to treat H. influenzae infections.